13Q14.3 DELETION PROBE

Chromosome region

• 13q14.2-q14.3

Description

Chromosome 13q abnormalities occur in 16-40% of multiple myeloma cases and are associated with poor prognosis¹,².A case study has shown that in 90% of patients, the 13q14 region was affected and 68% also showed involvement of the 13q21 region – the critical region in all but 8 patients was narrowed down to 13q14³. Deletions affecting 13q14 are also the most frequent structural genetic abnormalities in B-cell Chronic Lymphocytic Leukaemia (B-CLL)⁴. This region is found to be heterozygously deleted in 30-60% and homozygously deleted in 10-20% of CLL patients⁵. Recently though, the survival rate has been shown to be similar for the two groups⁶.Two non-coding RNA genes, DLEU1 and DLEU2, and the genetic marker D13S319, span the pathogenic critical region of 13q14⁷. DLEU1 is considered to be the most likely CLL-associated candidate tumour suppressor gene within the 13q14 region⁸. Subsequently, D13S319, located between the RB1 gene and D13S25 and within the DLEU1 locus, was found to be deleted in 44% of CLL cases⁹. It has also been postulated that a gene telomeric to the D13S319 region, encompassing D13S25, may be important in cases with hemizygous deletions and that this gene is a putative tumour suppressor gene¹⁰.

^{I am grateful for the excellent products I receive from Cytocell at a reasonable price, but more importantly the superb customer support.  The speed in which I receive answers or suggestions makes my life as a director much easier and allows me to focus on patient care.  The quality and consistency of Cytocell’s probes means I can trust the results, and my clients get their results in a timely manner. Dr. Theresa Brown, Hayward Genetics Center}